CD46 and acute myeloid leukemia: Results showed that both CD46 and CD55 were significantly downregulated by 2 to 7 folds in both AML and ALL patients compared to healthy controls which is suggestive of a defense mechanism conducted by leukemic cells to overcome immune defenses.